利民股份(002734.SZ):子公司取得投資項目備案證
格隆匯9月18日丨利民股份(002734.SZ)公佈,近日,公司全資子公司利民化學有限責任公司(以下簡稱"利民化學")取得由徐州市工業和信息化局發佈的《江蘇省投資項目備案證》【備案證號:徐工信備(2024)3號】,具體情況如下:
一、項目名稱
年產100噸新型高效多功能植保原藥技改項目
二、備案審批機構
徐州市工業和信息化局
三、項目概述
為進一步增強公司的核心競爭力,擬投資建設本項目。項目擬投資5,000萬元,項目建成後將形成年產100噸氟吡菌酰胺原藥產品生產能力
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.